Gujarat Themis Biosyn: Postal Ballot for Director Re-appointment & Related Party Transactions
Gujarat Themis Biosyn is seeking member approval via postal ballot for the re-appointment of Mrs. Kirandeep Madan as an Independent Director for a second term (May 1, 2026 - April 30, 2031). It also seeks approval for related party transactions with Themis Medicare Limited up to ₹50 Crores for FY26-27. E-voting is open from March 19 to April 17, 2026.
The re-appointment of an independent director and approval for related party transactions are significant corporate governance and operational matters that require shareholder consent and could impact future business dealings.
The announcement is a routine procedural notice regarding shareholder voting on director re-appointment and related party transactions. It does not contain any unexpected positive or negative financial news.
Gujarat Themis Biosyn Limited has issued a notice for a postal ballot to seek member approval on key resolutions. The primary resolutions include the re-appointment of Mrs. Kirandeep Madan as a Non-Executive Woman Independent Director for a second term of five years, effective May 1, 2026, to April 30, 2031. Additionally, the company is seeking approval for material related party transactions with Themis Medicare Limited (TML), not exceeding an aggregate value of ₹50 Crores for the Financial Year 2026-27, to be conducted on an arm's length basis.
The remote e-voting period for the postal ballot will commence on Thursday, March 19, 2026, at 9:00 a.m. IST and conclude on Friday, April 17, 2026, at 05:00 p.m. IST. The results of the postal ballot are expected to be declared by Tuesday, April 21, 2026. The company has engaged Central Depository Services (India) Limited (CDSL) to provide the remote e-voting facility. Detailed instructions for shareholders on how to participate in the e-voting process are provided, including procedures for both dematerialized and physical shareholding.
The company is also seeking approval for material related party transactions with Themis Medicare Limited (TML) for an aggregate value of up to ₹50 Crores for the Financial Year 2026-27. These transactions are to be carried out on an arm's length basis and in the ordinary course of business. The Board of Directors has been authorized to finalize terms and execute necessary documents.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under board meeting. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.